6:03 PM
 | 
Feb 13, 2015
 |  BC Extra  |  Company News

Intrexon acquires mucosal therapeutics play ActoGeniX

Synthetic biology company Intrexon Corp. (NYSE:XON) will acquire ActoGeniX N.V. (Zwijnaarde, Belgium) for $60 million. Intrexon will gain ActoGeniX's TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms, and a pipeline including two clinical candidates.

ActoGenix's AG013, an ActoBiotic genetically modified to express and secrete human trefoil...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >